Multiple Sclerosis Drugs Market Size In 2026: Regional Growth, Key Segments And Future Outlook
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Multiple Sclerosis Drugs Market Size, Value And Growth Trajectory Through 2030
The multiple sclerosis drugs market size has seen rapid expansion in recent years. It is anticipated to increase from $33.46 billion in 2025 to $37.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.6%. The market’s past growth can be ascribed to several factors, including the restricted availability of MS therapies, the rising prevalence of multiple sclerosis, heightened awareness among patients and medical practitioners, a dependence on interferon-based treatments, and the broadening of hospital and retail pharmacy networks.
The multiple sclerosis drugs market size is projected to undergo rapid expansion in the coming years. It is set to reach $61.43 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 13.0%. The anticipated growth during this period can be ascribed to the development of new monoclonal antibodies, the broadening of oral disease-modifying therapies, the integration of personalized medicine into MS treatment, increased investment in research and development for emerging therapies, and the rising adoption of digital health monitoring and telemedicine platforms. Prominent trends expected in the forecast period include the increasing uptake of disease-modifying therapies for multiple sclerosis, the advancement of personalized and targeted MS treatment approaches, the expansion of hospital and retail pharmacy distribution channels, a growing preference for oral and parenteral administration methods, and the emergence of novel immunomodulators, immunosuppressants, and monoclonal antibodies.
Get A Free Sample Report With In-Depth Market Insights:
Multiple Sclerosis Drugs Market Growth Factors: What’s Supporting Expansion?
The expansion of the multiple sclerosis drugs market is significantly bolstered by contributions from both governmental and non-governmental organizations. These bodies allocate funds to various programs and initiatives specifically designed to enhance the quality of life for individuals affected by multiple sclerosis (MS). For instance, the government of Alberta, in partnership with the Department of Economic Development, Trade, and Tourism in Canada, committed $1 million to the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo). This investment was intended to advance research and innovations, thereby improving the understanding and treatment of MS disease. CanProCo is an initiative that unites the efforts of nearly 50 MS researchers from diverse disciplines throughout Canada. The project subsequently received further funding from the Canada Brain Research, Biogen Canada, the MS Society of Canada, and Hoffmann-La Roche Limited (Roche Canada), culminating in a total of $10 million. Such consistent financial backing from governmental and non-governmental organizations effectively stimulates the growth of the multiple sclerosis drugs market.
Multiple Sclerosis Drugs Market Segment Landscape And Growth Outlook
The multiple sclerosis drugs market covered in this report is segmented –
1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes
2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores
3) By Route Of Administration: Oral Drugs, Parenteral Drugs
Subsegments:
1) By Immunomodulators: Glatiramer Acetate, Fingolimod, Teriflunomide, Dimethyl Fumarate
2) By Immunosuppressants: Natalizumab, Alemtuzumab, Ocrelizumab
3) By Interferons: Interferon Beta-1a, Interferon Beta-1b
4) By Other Drug Classes: Sphingosine 1-Phosphate Receptor Modulators, Monoclonal Antibodies, Other Emerging Therapies
Multiple Sclerosis Drugs Market Industry Trends: What’s Reshaping Demand?
Leading firms within the multiple sclerosis drugs market are concentrating on creating novel solutions aimed at boosting the effectiveness of treatments, elevating the quality of life for patients, and catering to the varied requirements of those afflicted with multiple sclerosis. These innovative solutions encompass fresh and inventive methods, offerings, or technologies conceived to effectively tackle particular difficulties or issues. An example of this is the announcement made in September 2024 by Genentech, a US-based biotechnology company, stating that the U.S. Food and Drug Administration (FDA) has granted approval for Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) to be used in the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo stands as the pioneering and sole subcutaneous injection, administered by medical professionals, which requires administration only twice a year and takes about 10 minutes, thereby offering individuals with MS further choices for their treatment.
Multiple Sclerosis Drugs Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the multiple sclerosis drugs market are Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Acorda Therapeutics Inc., EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alkermes plc, Amgen Inc., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation
View The Full Multiple Sclerosis Drugs Market Report:
Multiple Sclerosis Drugs Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the global multiple sclerosis drug market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
